Fatal diabetic ketoacidosis and antipsychotic medication

Journal of Forensic Sciences

Volumn 58, Issue 2, 2013, Pages 398-403

  Ely, Susan F ^a   Neitzel, Amber R ^b   Gill, James R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic medication; Atypical antipsychotics; Diabetes; Fatality; Forensic pathology; Forensic sciences; Ketoacidosis

Indexed keywords

2 PROPANOL; NEUROLEPTIC AGENT;

ADULT; BLOOD; CHEMICALLY INDUCED; DIABETIC KETOACIDOSIS; FEMALE; FORENSIC TOXICOLOGY; HUMAN; HYPERGLYCEMIA; MALE; MENTAL DISORDERS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

2-PROPANOL; ADULT; ANTIPSYCHOTIC AGENTS; DIABETIC KETOACIDOSIS; FEMALE; FORENSIC TOXICOLOGY; HUMANS; HYPERGLYCEMIA; MALE; MENTAL DISORDERS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84875509272     PISSN: 00221198     EISSN: 15564029     Source Type: Journal    
DOI: 10.1111/1556-4029.12044     Document Type: Article

References (61)

1. Moisan J, Gregoire JP, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005;14:427-36.
2. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504-14.
3. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-6.
4. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005;66:1463-7.
5. Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005;50:555-62.
6. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193:387-95.
7. Lieberman JA, 3rd. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6:8-13.
8. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry Suppl 2004;47:S87-93.
9. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-11.
10. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004;65:702-6.
11. Krosnick A, Wilson MG. A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus. Clin Ther 2005;27:320-6.
12. Dinan TG, Kohen D. Atypical antipsychotics and diabetic propensity: more questions than answers? Hum Psychopharmacol 2003;18:591-3.
13. Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol 2006;16:187-94.
14. Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol 2006;16:366-75.
15. Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005;20(Suppl 4):S349-57.
16. Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 2005;14:417-25.
17. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM, 3rd. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13:103-13.
18. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6.
19. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
20. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 2001;21:1448-54.
21. Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois ML, Vergnot V, et al. Diabetes as a result of atypical anti-psychotic drugs-a report of three cases. Diabet Med 2000;17:484-6.
22. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32.
23. Amdisen A. Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics. Acta Psychiatr Scand 1964;40(Suppl 180):411+.
24. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968;29:827-8.
25. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22:1440-3.
26. Tovey E, Rampes H, Livingstone C. Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 2005;19:207-10.
27. Takahashi M, Ohishi S, Katsumi C, Moriya T, Miyaoka H. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry 2005;38:183-4.
28. Meyer JM, Leckband SG, Loh C, Moutier CY. Quetiapine-induced diabetes with metabolic acidosis. Int Clin Psychopharmacol 2004;19:169-71.
29. Richards AA, Hickman IJ, Wang AY, Jones AL, Newell F, Mowry BJ, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006;26:232-7.
30. Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol 2005;20:33-7.
31. Meatherall R, Younes J. Fatality from olanzapine induced hyperglycemia. J Forensic Sci 2002;47:893-6.
32. Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001;21:1444-7.
33. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000;20:844-7.
34. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000;34:865-7.
35. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
36. Lambert BL, Chang KY, Tafesse E, Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol 2005;25:12-8.
37. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28.
38. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24:S7-14.
39. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63.
40. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27.
41. Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003;5:669-83.
42. Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:919-23.
43. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, et al. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC Psychiatry 2006;6:11.
44. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring Int Clin Psychopharmacol 2006;21(Suppl 2):S11-5.
45. Bowen DA. Hanging-a review. Forensic Sci Int 1982;20:247-9.
46. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
47. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001;14:278-82.
48. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62(Suppl 27):10-4.
49. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-21.
50. Guo JJ, Keck PE, Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006;67:1055-61.
51. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 2008;38:602-6.
52. DiMaio V, Sturner W, Coe J. Sudden and unexpected deaths after acute onset of diabetes mellitus. J Forensic Sci 1971;22:147-51.
53. Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forensic Med Pathol 2004;25:172-5.
54. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-52.
55. Coe JI. Use of chemical determinations on vitreous humor in forensic pathology. J Forensic Sci 1972;17:541-6.
56. Chaturvedi AK, Botch SR, Canfield DV, Forster EM. Vitreous fluid and/or urine glucose concentrations in 1335 civil aviation accident pilot fatalities. J Forensic Sci 2009;54:715-20.
57. Adams VI, Flomenbaum MA, Hirsch CS. Trauma and disease in Spitz and Fisher's medicolegal investigation of death. Springfield, IL: Charles C Thomas, 2006;436-59.
58. Gill JR, Goldfeder LB, Hirsch CS. Use of "therapeutic complication" as a manner of death. J Forensic Sci 2006;51:1127-33.
59. Jenkins AJ, Merrick TC, Oblock JM. Evaluation of isopropanol concentrations in the presence of acetone in postmortem biological fluids. J Anal Toxicol 2008;32:719-20.
60. Hess C, Musshoff F, Madea B. Disorders of glucose metabolism-post mortem analyses in forensic cases: part I. Int J Legal Med 2010;125:163-70.
61. Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol 2003;2:95-108.